Payment overview · 2025
General Payments
$1,573.37
98 reported records · 21 companies
Healthcare provider profile · identity verified
Grayson Jordan
Allopathic & Osteopathic Physicians|Family Medicine · HONEA PATH, SC · NPI 1578913976
Verified facts
What the public records show
CMS Open Payments records show Grayson Jordan received $1,573.37 in general payments during 2025 across 98 reported records.
ABBVIE INC. accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Qulipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $353.64 | 22.5% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $277.79 | 17.7% | 20 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $185.75 | 11.8% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.85 | 8.8% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $89.65 | 5.7% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $71.25 | 4.5% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.27 | 4.4% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $63.43 | 4.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.11 | 3.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $42.99 | 2.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.93 | 2.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.72 | 2.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.45 | 1.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.26 | 1.7% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.26 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.14 | 1.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.80 | 0.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.30 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.94 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.80 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.04 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,573.37 | 98 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $199.58 | 15 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $191.27 | 15 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $185.75 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $179.31 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $148.37 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $112.26 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $101.90 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $98.38 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $71.25 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $64.51 | 6 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $63.43 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $49.89 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $49.12 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $49.12 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.12 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $32.72 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.09 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $27.26 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 91 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 111 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 112 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
112 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 469 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 102 |
| Gabapentin | Gabapentin | 302 | 83 |
| Omeprazole | Omeprazole | 238 | 70 |
| Lisinopril | Lisinopril | 231 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 218 | 66 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 205 | 72 |
| Metformin Hcl | Metformin Hcl | 188 | 63 |
| Losartan Potassium | Losartan Potassium | 173 | 51 |
| Carvedilol | Carvedilol | 164 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 159 | 59 |
| Alprazolam | Alprazolam | 152 | 24 |
| Montelukast Sodium | Montelukast Sodium | 152 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 43 |
| Lorazepam | Lorazepam | 133 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 126 | 43 |
| Meloxicam | Meloxicam | 125 | 43 |
| Clonazepam | Clonazepam | 124 | 20 |
| Tramadol Hcl | Tramadol Hcl | 122 | 36 |
| Furosemide | Furosemide | 116 | 45 |
| Mounjaro | Tirzepatide | 112 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 31 |
| Jardiance | Empagliflozin | 111 | 27 |
| Trazodone Hcl | Trazodone Hcl | 111 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 110 | 25 |
| Glipizide Er | Glipizide | 109 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 97 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 29 |
| Sertraline Hcl | Sertraline Hcl | 95 | 24 |
| Eliquis | Apixaban | 91 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 23 |
| Prednisone | Prednisone | 84 | 67 |
| Simvastatin | Simvastatin | 84 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 22 |
| Pregabalin | Pregabalin | 82 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 37 |
| Ezetimibe | Ezetimibe | 73 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 14 |
| Celecoxib | Celecoxib | 70 | 23 |
| Ondansetron Odt | Ondansetron | 69 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 18 |
| Allopurinol | Allopurinol | 57 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 48 |
| Linzess | Linaclotide | 53 | 11 |
| Azithromycin | Azithromycin | 52 | 42 |
| Januvia | Sitagliptin Phosphate | 52 | 13 |
| Ozempic | Semaglutide | 50 | 19 |
| Alendronate Sodium | Alendronate Sodium | 47 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 19 |
| Famotidine | Famotidine | 46 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 43 |
| Mirtazapine | Mirtazapine | 43 | 12 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Atenolol | Atenolol | 40 | 11 |
| Donepezil Hcl | Donepezil Hcl | 40 | 12 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 14 |
| Glipizide | Glipizide | 37 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 22 |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | 12 |
| Diazepam | Diazepam | 32 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Naproxen | Naproxen | 32 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 23 |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 14 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 22 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 15 |
| Valsartan | Valsartan | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | 14 |
| Topiramate | Topiramate | 23 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,573.37 · 98 records | ABBVIE INC. | ABRYSVO, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FANAPT, GARDASIL 9, HETLIOZ, JARDIANCE, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, ROTATEQ, Rybelsus, SAPIEN 3 Ultra RESILIA, Symbravo, The Cologuard Plus Collection Kit, UBRELVY, VAXNEUVANCE, VOQUEZNA, VRAYLAR, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error